This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. UPDATE: June 24, 2025: This article has been updated to ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc., (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM) for patients with diabetes, announced today that it has received U.S. Food and Drug ...

FDA classifies this as a Class I recall, which means using the device could result in adverse health effects or death. Dexcom Inc., has recalled its G4 Platinum and G5 Mobile continuous glucose ...

SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, commends the expansion of CGM Medicare coverage to ...

Dexcom has received approval from the FDA for a new version of its smartphone connected Dexcom Share platform that will eliminate the docking cradle and allow a patient's continuous glucose monitor ...

The MXL-DPHY-DSI-RX-U-22ULP-22ULL is a high-frequency, low-power, low-cost, source-synchronous, physical Layer supporting the MIPI Alliance Specification for D-PHY v2.5. The PHY can be configured ...

VANCOUVER, Feb. 22, 2019 /CNW/ - Dexcom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM), today announced that the company has received Health Canada approval for its next ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Dexcom Inc. issued a recall of its ...